article thumbnail

Orphan Drug Costs; Digital Devices for Diabetes

Med Page Today

(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center.

article thumbnail

Medication Adherence in Patients with High LDL Cholesterol

HCPLive

They emphasize that poor medication adherence increases the risk of cardiovascular events and discuss factors such as drug cost, timing of administration, and the importance of adopting a patient-centric approach to optimize treatment success.

article thumbnail

Trends in direct health care costs among US adults with atherosclerotic cardiovascular disease with and without diabetes

Cardiovascular Diabetology

A key driver of the observed increase in direct costs was prescription drug costs, which increased by 37% among all individuals with ASCVD. Individuals with diabetes had a 1.5-fold fold higher mean expenditure that those without diabetes.

article thumbnail

Post-event follow-up costs in patients with atherosclerotic cardiovascular disease in Spain

Frontiers in Cardiovascular Medicine

The average costs per patient were €11,171 during the first year and €9,944 during the second year. Despite the perception that drug costs in the follow-up of chronic patients imply a high percentage of the costs, these accounted for only one tenth of the total amount.

article thumbnail

How to Get Free or Lower Cost Insulin for Your Medicare and Non-Medicare Patients: Shattering Barriers to Insulin Access

Cardiometabolic Health Congress

Part D Insulin Costs The Medicare drug plan can’t charge beneficiaries more than $35 for a one-month supply of each Part D-covered insulin, and they don’t have to pay a deductible. If Medicare beneficiaries receive a 3-month supply of insulin, their costs cannot exceed $105 ($35 for each month’s supply).

article thumbnail

Medicare Drug Cuts Target CVD Meds, Drive Debates

CardiacWire

Although truly reigning in these costs will require more than negotiating Medicare list prices, it’s clear that the government is finally taking action on drug costs, and that’s a step in the right direction (unless you work in pharma). The Takeaway The U.S.

article thumbnail

The High Cost of Insulin: Bridging Gaps on the Path to Affordable Care

Cardiometabolic Health Congress

This recent announcement by Sanofi to lower insulin costs is a step to ensure every American has access to this life-saving medication. With drug costs historically high and subject to inflation, there is an urgent need to develop and approve insulin alternatives that are effective and affordable for all.